Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Research

| More

Godrej Agrovet - Deflation in input prices leads to higher margin - ICICI Securities

Posted On: 2020-08-03 08:45:24


Three pointers to note from Godrej Agrovet's Q1FY21: (1) With reducing fear of coronavirus, there is MoM improvement in company's revenues. However, lower off-take from HoReCa will continue to impact rest of FY21, (2) deflation in input prices for all segments will lead to better gross and EBITDA margin in FY21 and (3) the company has continued to focus on reduction in working capital which will lead to higher return ratios. We expect most segments of the company to show recovery in H2FY21 after weak H1FY21 with normal monsoon and improved agri outlook. We remain confident of value creation (RoE > Cost of Equity), but believe stock price upside is capped at current valuations of 25x FY22E. Maintain HOLD with a DCF-based revised target price of Rs473 (26x FY22E; Earlier TP-Rs401).

- Lower revenues of Dairy and Animal feed segment: Godrej Agrovet reported revenue decline of 8.7% and PAT growth of 16.5% YoY. Animal feed and Dairy segment revenues declined 15.5% and 26.2%, respectively due to lockdown as well as lower institutional sales. With higher palm oil prices, palm oil segment reported 8.2% revenue growth. Due to 45.4% higher revenues of Astec, Crop protection segment reported 11.9% higher revenues.

- Deflation in input prices leads to higher gross margin: The company reported 330bps higher gross margin. The input prices for all the segments were lower YoY. We also note the company initiated cost saving measures during the quarter. The change in revenue mix (Higher share of Astec and palm oil) also helped to improve the margins at consolidated level. With lower taxes, PAT expanded 16.5% YoY.  Expect a better Agri season: With normal monsoon, 14% higher sowing and increase in Government spends in FY21, we expect the company to be net beneficiary of strong agri season. We also model the company's EBITDA margin to improve in rest of FY21 due to lower input prices.

- Weak demand from HoReCa to continue to impact off-take: HoReCa accounts for ~30% consumption of agri products such as chicken, milk, palm oil. With lower demand from HoReCa and institutions, we expect the company's revenues to remain impacted in rest of FY21. There will be some increase in in-home consumption. Muted celebrations in festivals and postponement of marriages and other events will also hurt the demand for company's products.

- Maintain HOLD: We expect GAVL to report revenue and PAT CAGRs of 6.9% and 5.3% respectively, over FY20-FY22E. Though we remain confident of value creation with RoE > Cost of Equity, we believe upside to the stock price is limited at current valuations. Maintain HOLD with a DCF based target price of Rs473 (26x FY22E).

Shares of Godrej Agrovet Ltd was last trading in BSE at Rs.470.8 as compared to the previous close of Rs. 458.7. The total number of shares traded during the day was 33709 in over 1193 trades.

The stock hit an intraday high of Rs. 478 and intraday low of 463.6. The net turnover during the day was Rs. 15827500.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Mazagon Dock IPO fully subscribed on Day 1 - Angel Broking

Pharma - Sector Thematic - Cardiac: the heartbeat of domestic market - HDFC Securities Institutional Research Desk

Walmart-Tata Retail Deal - Mr. Himanshu Nayyar, YES SECURITIES

HDFC Securities Institutional Research Desk: Chemical Conference Report

Lupin - Launch of Fosaprepitant - Angel Broking

Infosys - Key beneficiary of increased IT spending - Angel Broking

Gateway Distriparks - Holding structure simplified; prepared for next phase of growth - ICICI Securities

Visaka Industries - Demand and pricing tailwinds sustain; maintain a compelling BUY - ICICI Securities

GSK Pharmaceuticals - Analyst call highlights - Sep 28, 2020 - ICICI Securities

HeidelbergCement India - Play on better priced Central India; initiate with BUY - ICICI Securities

Healthcare - Diagnostics: Multiple tailwinds likely to emerge - ICICI Securities

Mazagon Dock Shipbuilders Ltd - IPO Review - ICICI Securities

Persistent Systems - 28th September 2020 - Angel Broking

Canara Bank - 28th September 2020 - Angel Broking

Subscribe to UTI Asset Management Company Limited - IPO Note - Angel Broking

Multiplex Sector - Mr. Jyoti Roy - DVP - Equity Strategist, Angel Broking Ltd

Sale of Sequent stake to Strides Pharma - Angel Broking

Subscribe to Mazagon Dock Shipbuilders Ltd - IPO Note - Angel Broking

JSW Energy - First big renewable step - ICICI Securities

V-MART Retail - Best play in value fashion segment; initiating with BUY - ICICI Securities

Gas sector - New winners and losers likely on policy changes in gas sector - ICICI Securities

Mazagon Dock Shipbuilders Limited - IPO Note - Geojit

UTI Asset Management Company Limited - IPO Note - Geojit

Preview on RBI Monetary Policy - Oct 2020 - Shanti Ekambaram

Rollover Report for September 2020 - October 2020: Angel Broking

Covid Recovery Pulse - Sep 25, 2020 - ICICI Securities

Quick Comment - Suven Pharmaceuticals - ICICI Securities

Derivatives Strategy - Sep 25, 2020 - Positional Option - ICICI Securities

Gladiator Stocks - Ramco Cement - ICICI Securities

IPO Review - UTI Asset Management Company - ICICI Securities

Stock of the Day - Zensar Technologies - Sep 25, 2020 - Angel Broking

Accenture Q4FY2020 Result - Angel Broking

Granules India receives ANDA approval - Angel Broking

Zydus Cadila receives US FDA approval - Angel Broking

Cipla - ANDA approval - Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd

Mindspace REIT - Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd

UTI AMC - IPO - Mr. Jaikishan Parmar - Sr. Equity Research Analyst, Angel Broking Ltd

Balkrishna Industries - Growth momentum continues - ICICI Securities

Rollover Analysis (September 25): Nifty starts October series with low OI amid high volatility

Derivatives View (September 25): Sell Bank Nifty in range of 20650-20750 - ICICI Securities

Rollover Analysis - Sept 20: Selling climax on expiry as markets crumble - YES Securities

Zydus Wellness - Leadership in niche categories; initiate at BUY - ICICI Securities

Power - Setting the stage - ICICI Securities

Company Update - Elgi Equipments - ICICI Securities

Nano Nivesh - The Anup Engineering - ICICI Securities

RBI OMO announcement of Rs. 10000 crore - Angel Broking

TCS deal win - Sep 24, 2020 - Angel Broking

View on Pre-Monetary Policy by Upasna Bhardwaj, Senior Economist at Kotak Mahindra Bank

US FDA approval to Zydus Cadila - Angel Broking

HDFC Securities Institutional Research Desk: Cement Sector Thematic - Spotting the sweet spot







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019